GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Q3 FY27 Profit Rises 22% to ₹766 Million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 28 Oct 2026, 06:40 PM IST  ·  BSE ID: 0e542706-4dc4-4283-9977-20570dd02a8b
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported higher quarterly profit and revenue, with nine-month figures also showing growth.
🤖 AI Summary
  • Profit for the period was ₹766 Million for Q3 FY27, a 21.78% increase over Q3 FY26.
  • Revenue from Operations reached ₹2,631 Million for the quarter ended September 30, 2026.
  • Basic and diluted earnings per share (not annualised) stood at ₹33.26 for Q3 FY27.
  • For the nine months ended September 30, 2026, Revenue from Operations was ₹7,280 Million.
  • Profit for the nine months ended September 30, 2026, was ₹2,132 Million.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q3 FY27)
2,631 Million
12.48%
Profit for the period (Q3 FY27)
766 Million
21.78%
Basic and diluted EPS (Q3 FY27)
33.26
21.78%
Revenue from Operations (Nine Months FY27)
7,280 Million
16.03%
Profit for the period (Nine Months FY27)
2,132 Million
22.81%
🏢 How This Affects the Company
📈
Business Impact
Domestic sales grew by 19% for the quarter and 15% for the nine months, aided by product relaunches, indicating market share gains and volume expansion.
💰
Financial Impact
Profit for the period increased by 21.78% to ₹766 Million for the quarter, and by 22.81% to ₹2,132 Million for the nine months, driven by revenue growth.
⚙️
Operational Impact
The successful relaunch of Combiflam Suspension and Allegra Suspension/Depura Kids in previous periods has contributed to the current domestic sales growth.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which showed increased profit and revenue for the quarter and nine months.
🔍
Management Signal
The management's commentary highlights disciplined strategy execution, volume expansion, and investments in brand building and distribution.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q4 FY27 financial results — observe sustained revenue and profit growth.
Domestic sales growth — verify if 19% quarterly growth rate is maintained.
Future product launches or expansions — monitor management announcements.
LOW RISK The financial results indicate stable performance with consistent growth and no new risks identified.
💡 Investor Takeaway
Sanofi Consumer Healthcare India Limited reported a Profit for the period of ₹766 Million for the quarter ended September 30, 2026, an increase of 21.78% from ₹629 Million in Q3 FY26. Revenue from Operations for the quarter grew 12.48% year-on-year to ₹2,631 Million.
⚖️ Strengths & Concerns

✅ Positives

  • Profit for the period increased by 21.78% year-on-year to ₹766 Million for the quarter ended September 30, 2026.
  • Revenue from Operations grew by 12.48% year-on-year to ₹2,631 Million for the quarter ended September 30, 2026.
📅 Company Track Record
Sanofi Consumer Healthcare India Limited emerged as a distinct legal entity following its demerger from Sanofi India Limited on June 1, 2024. The company has previously reported Q1 FY27 profit of ₹688 Million on revenue of ₹2,357 Million, and Q2 FY27 profit of ₹766 Million on revenue of ₹2,631 Million, indicating consistent growth.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Sanofi Consumer Healthcare India Limited's Profit for the period in Q3 FY27?
Sanofi Consumer Healthcare India Limited's Profit for the period was ₹766 Million for the quarter ended September 30, 2026, an increase from ₹629 Million in the same quarter last year.
What was Sanofi Consumer Healthcare India Limited's Revenue from Operations for the quarter ended September 30, 2026?
The company's Revenue from Operations for the quarter ended September 30, 2026, was ₹2,631 Million, up from ₹2,339 Million in the corresponding prior period.
What were the nine-month financial results for Sanofi Consumer Healthcare India Limited?
For the nine months ended September 30, 2026, Revenue from Operations was ₹7,280 Million, and Profit for the period was ₹2,132 Million.
What was the Basic and diluted earnings per share for Sanofi Consumer Healthcare India Limited in Q3 FY27?
Basic and diluted earnings per share (not annualised) for the quarter ended September 30, 2026, was ₹33.26.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.